Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ParActin is a **proprietary, patented, standardized extract** of the plant *Andrographis paniculata*, containing andrographolide, 14-deoxyandrographolide, and neoandrographolide as principal active ingredients. This extract is designed to **support healthy inflammatory responses, joint, cartilage, bone, muscle, and immune health**. Its mechanism centers on inhibiting **NF-kappa B** (a master regulator of inflammation) and activating the **PPAR gamma receptor**, both of which are implicated in the regulation of pro-inflammatory cytokines and proteins. ParActin is marketed primarily as a **dietary supplement** and is not FDA-approved as a pharmaceutical drug. It is available in oral and topical formulations, and has been studied for its potential effects on pain, inflammation, and autoimmune disease. Clinical evidence primarily supports use for mild to moderate joint pain, musculoskeletal discomfort, and inflammatory conditions, but broader claims require further study[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ParActin.